Study maps structural aging across human tissues, identifying SIRT6-regulated vascular trajectories

Researchers have developed PathStAR, a computational framework that maps tissue-specific structural aging trajectories from histopathology images, demonstrating that SIRT6 variants are specifically associated with accelerated vascular aging.

Researchers published a study in Nature Aging introducing PathStAR (Pathology-based Structural Aging Rate), a computational framework that quantifies tissue structural aging from hematoxylin and eosin (H&E) histopathology images without training on chronological age.

The model was applied to 25,306 post-mortem biopsies spanning 40 tissue types from 970 Genotype-Tissue Expression (GTEx) donors aged 21–70 years.

The analysis revealed three distinct temporal trajectories: early aging (vascular tissues showing peak deterioration in the 30s), late aging (uterus and vagina accelerating in the 50s), and biphasic aging (digestive and male reproductive tissues displaying acceleration peaks in both the 30s and 50s).

A genome-wide association study of individual structural aging deviation scores (ΔSA) identified 123 significant genes, with SIRT6 variants showing a highly specific association with accelerated vascular structural aging (P = 0.0000256 in the tibial artery).

Traditional molecular clocks assume linear trajectories and cannot resolve the nonlinear remodeling of tissue physical structures that directly underlies organ functional decline.

Periods of accelerated structural aging across multiple organs are defined by a universal molecular shift: the upregulation of inflammatory pathways (such as TNF via NFKB) alongside the simultaneous suppression of oxidative phosphorylation, DNA repair, and quality control systems.

The discovery of coordinated cross-organ aging within individuals—such as a synchronized deterioration axis between digestive and male reproductive organs (r = 0.14–0.43)—suggests shared systemic hormonal regulation that links aging rate across traditional system boundaries.

The quantitative mapping of tissue-specific acceleration windows suggests that geroprotective interventions must be temporally scheduled, indicating that vascular therapeutics may require early-adulthood administration while reproductive interventions are best matched to post-menopausal windows.

The specific genetic linkage of SIRT6 to vascular structural integrity provides empirical support to biotechnology platforms targeting SIRT6 to address cardiovascular and age-related tissue degeneration.

Further validation of the PathStAR framework on larger clinical datasets to determine if therapeutic interventions can preserve or restore youthful tissue architecture.

The development of blood-based biomarkers that correlate with the tissue-specific structural deviation scores identified by the platform.